IKIlya Andreevich Kofiadi

Ilya Andreevich Kofiadi

*This is an algorithmically generated author record based on publicly available information.

Ilya Andreevich Kofiadi has a total of 272 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TREC and KREC concentration in the screening of inborn errors of immunity

    by Gulnara G. Suleymanova, Vladislav A. Vasilichin, Nailya Kh. Setdikova, Evgeniy A. Frolov, Tatiana N. Myasnikova, Tatiana S. Romanova, Nikolay A. Nazarov, Tatiana V. Latysheva, Il’YA A. Kofiadi, Elena A. Latysheva, et al.

    BACKGROUND: The lack of accessible screening for inborn errors of immunity in adults significantly complicates the diagnosis of these conditions. In more than half of the cases, this leads to delayed disease detection and the development of irreversible complications in patients. AIM: To determine reference intervals for TREC and KREC concentrations in adults and evaluate the possibility of their use for inborn errors of immunity screening using the “NeoScreen SMA/TREC/KREC” test system. METHODS: A single-center observational cross-sectional controlled non-randomized study was conducted involving 101 patients. The study included groups with humoral and combined immune defects, divided into subgroups with predominant humoral immune defects (antibody synthesis disorders) and combined immune defects, as well as a control group of conditionally healthy participants. TREC and KREC levels were determined using polymerase chain reaction. The study was conducted from September 2024 to August 2025. Statistical analysis included group comparisons (Mann–Whitney and Kruskal–Wallis tests), ROC analysis. Reference intervals were determined using the direct method according to International Federation of Clinical Chemistry and Laboratory Medicine recommendations. Statistical significance was confirmed at p 0,05. RESULTS: The study included 101 participants: 46 patients in the control group and 55 patients with inborn errors of immunity. Statistically significant differences in TREC and KREC levels were observed between healthy participants under 39 years and over 40 years (p 0,001 and p = 0,003, respectively). Subgroup analysis showed: in the humoral immune defects subgroup, KREC levels demonstrated area under curve — 0,87, specificity — 95 %, sensitivity — 68 %. In the subgroup with combined immune defects, the method did not show statistically significant differences with the control group when comparing TREC and KREC levels (p = 0,639 and p = 0,092, respectively). CONCLUSION: The development of separate threshold values for patients over 40 years of age is required. The method is effective for screening humoral immune disorders but is not suitable for combined forms of inborn errors of immunity. Despite the high specificity and sensitivity of KREC as a diagnostic marker, the method cannot be recommended as a replacement for existing diagnostic methods due to the availability of more accessible and effective screening approaches.

  • Open Access

    Refined Design and Liquid-Phase Assembly of GalNAc-siRNA Conjugates: Comparative Efficiency Validation in PCSK9 Targeting

    by Nikolai A. Dmitriev, Petr V. Chernov, Ivan S. Gongadze, Valeriia I. Kovchina, Vladimir N. Ivanov, Artem E. Gusev, Igor P. Shilovskiy, Ilya A. Kofiadi, Musa R. Khaitov

    The development and application of therapeutic oligonucleotides, such as siRNA, miRNA, ASOs and aptamers, is a rapidly growing field in biomedicine. These molecules are undergoing extensive preclinical and clinical testing, and the market for synthetic RNA drugs is expanding. However, several challenges remain, including targeted delivery and high costs associated with development, screening and production. One significant advance has been the creation of GalNAc-conjugates, which selectively target ASGPR and deliver oligonucleotides to hepatocytes. Although these conjugates have shown promising results, their widespread use is limited by the lack of effective synthesis methods. Thus, the development of new methods for the synthesis of ligand-oligonucleotide conjugates is an important task to which this study is devoted. In this study, we created a library of siRNA conjugates with the GalNAc L-96 ligand to suppress the expression of the PCSK9 gene associated with elevated LDL and an increased risk of developing cardiovascular diseases. The selection of the most effective siRNA molecules was carried out using an algorithm previously developed by our research group, which considers thermodynamic stability, predicted specificity and effectiveness. To experimentally confirm the effectiveness of conjugates, an in vitro model based on the cultivation of hepatocyte cells was developed. Optimization of the conjugate synthesis process has significantly reduced the cost of manufacturing technology, which creates the potential for efficient scaling of synthesis for transfer and application in the pharmaceutical industry. The results of the study showed that the development of the siRNA sequence optimized in silico resulted in a significant increase in the inhibitory effect of the GalNAc-siRNA conjugate compared to a compound similar to a commercial drug.


  • Open Access

    Approach to Design of Potent RNA Interference-Based Preparations Against Hepatocellular Carcinoma-Related Genes

    by Petr V. Chernov, Vladimir N. Ivanov, Nikolai A. Dmitriev, Artem E. Gusev, Valeriia I. Kovchina, Ivan S. Gongadze, Alexander V. Kholstov, Maiia V. Popova, Dmitry A. Kudlay, Daria S. Kryuchko, et al.

    Every year, the scientific community continues to drive advances in healthcare, opening up new perspectives in the treatment and management of various diseases. Despite vast strides being made in the quality of life and longevity, we still face an equally significant growth in the burden of oncological pathologies. Although current trends lean towards preventive and personalized medicine, numerous hurdles remain to be cleared to develop robust strategies in the field of oncology. Among all types of tumors, one of the prominent positions is occupied by hepatocellular carcinoma (HCC), which is one of the most widespread primary cancers with a high mortality rate. Conventional approaches to HCC therapy, such as surgery or chemotherapy, rarely provide steady performance due to the highly polymorphous nature of the cancerous process. In this study, we suggest an alternative methodological framework for designing potent siRNAs targeting genes implicated in hepatocellular carcinoma, implementing RNA interference mediated by synthetic small interfering RNAs (siRNAs) against mRNAs of ITGB1 and CD47 genes. Products of these genes are renowned drivers of tumor progression. We have developed a software algorithm for the design of unmodified and modified siRNAs, carried out solid-phase synthesis of the most promising molecules, and proved their capability to perform a more than 50-fold suppression of expression of the target genes in vitro.

  • T-cell receptor repertoire clonal diversity and structure in C57BL/6-BALB/c hematopoietic chimeras

    by O.S. Nikitina, Yu.V. Vasileva, P.V. Chernov, V.A. Vasilichin, I.A. Kofiadi, A.D. Donetskova, A.N. Mitin

  • Alteration of the epigenetic profile of FOXP3 in regulatory T-cells mediated by allergen immunotherapy

    by D.O. Timoshenko, V.A. Vasilichin, A.A. Osokin, O.S. Nikitina, G.O. Gudima, O.M. Kurbacheva, I.A. Kofiadi

  • Open Access

    Single cell RNA sequencing: modern approaches and achievements

    by Artem E. Gusev, Petr V. Chernov, Nikolai A. Dmitriev, Ilya A. Kofiadi

    Relevance. Single-cell RNA sequencing (scRNA-seq) is a modern approach to studying the diversity and heterogeneity of RNA transcripts in individual cells, as well as to identifying the composition of different cell types and functions in organisms, organs, and tissues. Based on NGS (next-generation sequencing), scRNA-seq provides a vast amount of information at high cellular resolution in various fields, enabling new discoveries in understanding the composition and interaction patterns of individual cell types in humans, animal models, and plants. Despite its rapid development, optimization, and automation worldwide over the past 15 years, scRNA-seq remains relatively new and has only recently been used in Russia. The challenge of mastering and successfully implementing this method is urgent and critical - it is a powerful tool for in-depth analysis and diagnostics, as demonstrated by the results of studies in which it has been used. The aim of the review was to examine the basic principles and steps of scRNA-seq implementation, both in terms of technical implementation and sample preparation as an extension of the classic NGS method, as well as in terms of the complexity and expansion of data processing, and the use of new algorithms and databases. We examined commercially available scRNA-seq technologies and technologies described in scientific literature that have served as prototypes and alternatives. We also examined examples and results of the use of such technologies in various fields of science and medicine, such as oncology, senescence, diagnostics, and clinical trials. Conclusion. Development and successful application of the scRNA-seq method in scientific and clinical practice will become the key to a wide range of future discoveries and successful accurate personalized diagnostics and healthcare.

  • Open Access

    Development and validation of algorithms for the search, evaluation and modification of siRNAs applicable to the treatment of pathologies of the immune system using the model of the APOB gene

    by P.V. Chernov, N.A. Dmitriev, A.E. Gusev, A.V. Kholstov, M.V. Khodzhava, V.I. Kovchina, T.E. Rusak, I.P. Shilovskiy, D.A. Kudlay, I.A. Kofiadi

    Разработка и валидация алгоритмов поиска, оценки и модификации миРНК, применимых для терапии патологий иммунной системы, на примере гена APOB


  • Open Access

    A Novel Pot-Economy Approach to the Synthesis of Triantennary GalNAc-Oligonucleotide

    by Artem Evgenievich Gusev, Vladimir Nikolaevich Ivanov, Nikolai Andreevich Dmitriev, Aleksandr Viktorovich Kholstov, Vladislav Aleksandrovich Vasilichin, Ilya Andreevich Kofiadi, Musa Rakhimovich Khaitov

    N-Acetylgalactosamine (GalNAc) is an efficient and multifunctional delivery tool in the development and synthesis of chemically modified oligonucleotide therapeutics (conjugates). Such therapeutics demonstrate improved potency in vivo due to the selective and efficient delivery to hepatocytes in the liver via receptor-mediated endocytosis, which is what drives the high interest in this molecule. The ways to synthesize such structures are relatively new and have not been optimized in terms of the yields and stages both in lab and large-scale synthesis. Another significant criterion, especially in large-scale synthesis, is to match ecological norms and perform the synthesis in accordance with the Green Chemistry approach, i.e., to control and minimize the amounts of reagents and resources consumed and the waste generated. Here, we provide a robust and resource effective pot-economy method for the synthesis of triantennary GalNAc and GalNAc phosphoramidite/CPG optimized for laboratory scales.


  • Open Access

    Personalized approach to the biologicals’ selection in patients with severe asthma: real practice tools and new possibilities

    by K. S. Pavlova, D. O. Timoshenko, A. A. Osokin, I. A. Kofiadi, O. M. Kurbacheva

    Currently, the most effective approach to treating patients with severe uncontrolled asthma is the use of biologicals. These treatments are highly effective and safe, but not universal. Different biologicals block various parts of asthma pathogenesis. Also, biologicals have different effectiveness in relation to comorbidities. In this regard, the targeted therapy selection should be personalized, endotypeand phenotype-oriented.The aim of this review was to analyze the literature data on methods for personalized biologicals’ selection in patients with severe asthma that are currently used in clinical practice, as well as new prospects in this area.Conclusion. Laboratory and instrumental examination methods currently used for endoand phenotyping of severe asthma help in identifying the key pathogenetic factor in the disease development that serves as a basis for selection of the biological. However, biomarkers identified during routine examination are not absolute and are prone to exceptions. Also, the targeted therapy selection is based on a subjective determination of the prevailing pathogenetic mechanism when a patient with severe asthma has a mixed disease phenotype and meets the criteria for prescribing all available biologicals. Therefore, the search for biomarkers that predict the effect of a particular biological remains a relevant direction for future studies. The combined use of clinical, molecular-genetic examination results and evaluation of epigenetic markers can help in solving this problem. This review provides current data on the biologicals used in severe asthma treatment, the phenotyping and endotyping tools used in real practice, and also describes promising areas of the epigenetic biomarkers research.


  • Open Access

    Application of therapeutic nucleic acids and RNA interference to create products for personalised medicine

    by I. P. Shilovskiy, G. B. Pasikhov, V. V. Smirnov, I. A. Kofiadi, M. V. Popova, P. A. Strueva, M. R. Khaitov

    INTRODUCTION. Small interfering RNAs (siRNAs) are among the most promising types of therapeutic nucleic acids aiming at the inhibition of pathogenetically relevant gene expression through the RNA interference mechanism. However, the limited bioavailability and immunogenicity of siRNAs and imperfect delivery systems hinder the clinical potential and applicability of siRNA medicinal products.AIM. This study aimed to summarise recent advances in the development of siRNA medicinal products and the corresponding delivery systems, review clinical trial results, and outline future development prospects for these medicinal products.DISCUSSION. This article covers the molecular mechanisms underlying RNA interference, the considerations for siRNA development, and the techniques for effective siRNA delivery. The article dwells upon various systems for nucleic acid delivery to targeted cells. The most promising delivery systems are non-viral systems, including liposomes, exosomes, nanoparticles, polymers, cell-penetrating peptides, and GalNAc ligands. Their main advantages include their ease of complexation with nucleic acids, modification and functionalization potential, favourable safety profile, ability to cross biological barriers, and tropism to target tissues. The article summarises the information that has accumulated over the past few years in clinical trials of siRNA medicinal products for a range of conditions, including metabolic disorders, infections, and cancers, as well as hereditary, ophthalmic, renal, and hepatic diseases. Special attention is paid to siRNA medicinal products undergoing clinical trials (over 10 products) and approved for clinical use (6 products, including MIR 19, the first authorised Russian siRNA medicinal product).CONCLUSION. Ultimately, siRNA medicinal products are a promising tool for personalised medicine, exhibiting therapeutic potential for a wide range of pathological conditions. Further studies of siRNA medicinal products should aim at improving siRNA production technology to increase their bioavailability and half-life period. In addition, these studies should aim at enhancing delivery systems for these products to mitigate toxicity risks and maximise efficacy.